Navigation Links
Jak3 in Medical News

Researchers identify new cell targets for preventing growth of breast and other tumors

...e proteins encoded by the candidate genes. They found that seven of the genes encoded membrane or secreted proteins. Four of these namely FAP, SFRP2, jak3 and SMPD3 had not just increased gene expression, but also increased protein expression in breast tumor vessels, and thus could be good targets for t...

St. Jude researchers find key step in programmed cell death

...e to keeping cells alive. For example, they demonstrated earlier that most cytokines controlling hematopoietic cells require an enzyme called Jak2, or jak3 in lymphocytes, at the receptors where cytokines attached to the cell. In screening for components that are regulated by the Jak enzymes, the St. J...

Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research

...vanced Phase 2 clinical studies for RA and ITP this year, and also a Phase 2 clinical study in systemic lupus erythematosus. In addition, Rigel's oral jak3 inhibitor, R348, is currently in a Phase 1 study for the potential treatment of psoriasis and RA. "Dan comes to Rigel with solid clinical research l...

New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer

...samples later identified two more mutations in the jak3 gene. Thomas Mercher, a postdoctoral fellow ... a mouse model. "It was important to show that the jak3 mutation, when introduced in mice, would lead to a...leukemia-like illness. It did, confirming that the jak3 mutations play a central role in leukemia," said G...
Jak3 in Medical Technology

Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders

...8 in young, healthy males using a double blind, placebo controlled, single dose and multiple rising doses of R348. Results are expected in mid-2008. jak3 in RA and Other Immune Disorders RA affects approximately 1% of the population worldwide -- approximately 2.1 million Americans -- and is a debilita...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

...es. XL019 is a potent JAK2 inhibitor (IC50 = 2 nM) with excellent selectivity versus the other members of the JAK kinase family (JAK1 IC50 = 130 nM, jak3 IC50 = 250 nM, TYK2 IC50 = 340 nM). It is active against both wild type and mutationally activated forms of JAK2, and in preclinical studies showed go...

Pharmacopeia Announces Third Quarter 2007 Financial Results

..., coupled with resources expended on the company's jak3 program. The expense for the jak3 program has been primarily classified as collabora...Prior to 2007, resources expended on the company's jak3 program were classified as proprietary research an...
Jak3 in Biological News

New strategy rapidly identifies cancer targets

...amples later identified two more mutations in the jak3 gene. Thomas Mercher, a postdoctoral fellow i...a mouse model. "It was important to show that the jak3 mutation, when introduced in mice, would lead to...eukemia-like illness. It did, confirming that the jak3 mutations play a central role in leukemia," said...
Jak3 in Biological Technology

Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders

...considerable opportunity to unlock value in both stocks. "Cytopia is a world class drug development company with drug candidates ranging from the jak3 program partnered with global pharmaceutical company Novartis through to CYT997, a vascular disrupting agent which is now in Phase II clinical studies...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

...igel plans to focus on psoriasis and possible topical applications with its jak3 inhibitor, R348, and to do so with a collaboration partner. Rigel will move...hibitor compound for transplant rejection. Rigel expects to select this new jak3 inhibitor compound by the end of 2008. Rigel will proceed on its own with t...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

...logy to the discovery and development of innovative small-molecule kinase inhibitors targeting key inflammatory mediators such as PI3Kg and d, Zap-70, jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. In addition...
Other Tags
(Date:7/28/2014)... a healthy lifestyle may help childhood cancer survivors reduce ... indicates. Researchers suggested that children with cancer and ... about how their diet and certain behaviors could ... are important because they indicate that adults who were ... influence their own health outcomes," said one of the ...
(Date:7/28/2014)... 28, 2014 Glidewell Laboratories announced today ... have successfully passed the five-year mark in clinical usage, ... million units prescribed by US dentists. , Even as ... with good results from respected clinical studies, many dentists ... perform over extended years of clinical service before they ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 This ... Global and Chinese Tadalafil industry. The report firstly ... classification, application and manufacturing technology. The report then ... listing their product specification, capacity, Production value, and ... quantitatively 2009-2014 global and China’s total market of ...
(Date:7/28/2014)... Raleigh, NC (PRWEB) July 28, 2014 ... they say is an improved blood test for the ... article on the new research. Click here to ... of Respiratory Medicine at Tokyo’s Juntendo University Graduate School ... biomarker called N-ER/mesothelin is a step above the old ...
(Date:7/28/2014)... July 28, 2014 Community Health Center ... medical, dental, and pharmacy services, has released an article ... chronic disease management . Founded in 1983, the health ... those of the county that face barriers to obtaining ... make an appointment at the CHC, click here: ...
Breaking Medicine News(10 mins):Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
Other Contents